CC
UNCY icon

Centiva Capital’s Unicycive Therapeutics UNCY Stock Holding History

Centiva Capital’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,519
Closed -$19.4K – 2111
2023
Q2 		$19.4K Buy
+1,519
New +$23.7K ﹤0.01% 1539

Other funds holding UNCY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $238M AUM 38.59% 1-Year Est. Return

Centiva Capital's UNCY Position: Q3 2023 in Review

Centiva Capital sold out of Unicycive Therapeutics (UNCY) in Q3 2023, closing a stake of 1,519 shares — an estimated $19.4K sold.

Centiva Capital first reported a position in UNCY in Q2 2023 and held it in 1 quarter. The position peaked at $19.4K in Q2 2023. 16 funds tracked by Wall St. Rank hold UNCY as of Q3 2023.

  • Centiva Capital reported no remaining Unicycive Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Centiva Capital sold 1,519 Unicycive Therapeutics shares in Q3 2023, an estimated $19.4K.
  • Centiva Capital first reported a position in Unicycive Therapeutics in Q2 2023 and held it in 1 quarter.
  • Centiva Capital's Unicycive Therapeutics position peaked at $19.4K in Q2 2023.
  • 16 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.